Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and ...

Nebraska shows how America’s Heartland can power U.S. bioeconomy leadership by linking innovation in agriculture, research, ...

Apogee Therapeutics — The biotechnology company soared 50% after AbbVie confirmed it will acquire the company. The $10.9 ...

Scientists pieced together the genetic history of Acinetobacter baumannii — a notoriously stubborn hospital pathogen — using ...

Known by acronyms that need no explanation, viruses like COVID, SARS and Ebola conjure images of medics in protective suits ...

This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight ...

A former executive at the buyout firm told his lawyer of alleged alcohol and drug-fuelled parties and said one of its businesses was a “drug-fuelled pit”.

Add Yahoo as a preferred source to see more of our stories on Google. A little-noticed provision in next year’s defense bill has united an unusual coalition of progressive Democrats and conservatives, ...

While investors are focused on AI and Big Tech, Bank of America says they should also be looking at the mid-cap segment for ...

AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.

New research at Carilion Clinic and Virginia Tech’s Fralin Biomedical Research Institute at VTC is positioning Southwest ...

Headlining Evaluate’s forecast is Eli Lilly’s diabetes and obesity med tirzepatide, which the Evaluate team figures will be worth more than $70 billion by 2032 (wildpixel/iStock/Getty Images Plus) ...